A Cost-Effectiveness Analysis of Fingolimod Versus Dimethyl Fumarate As A Second-Line Disease Modifying Treatment In Patients With Highly Active Relapsing-Remitting Multiple Sclerosis
Abstract
Authors
M Raikou M Kalogeropoulou G Rombopoulos